The current financial score of Abeona Therapeutics Inc is 8.69. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.38M, representing a year-over-year increase of 2745.00%, while its net profit experienced a year-over-year increase of 118.55%.
The current valuation score of Abeona Therapeutics Inc is 7.44. Its current P/E ratio is 4.23, which is 61.70% below the recent high of 6.84 and 429.73% above the recent low of -13.94.
The current earnings forecast score of Abeona Therapeutics Inc is 8.86. The average price target is 18.88, with a high of 30.00 and a low of 14.00.
The current price momentum score of Abeona Therapeutics Inc is 3.58. Currently, the stock price is trading between the resistance level at 5.95 and the support level at 5.06, making it suitable for range-bound swing trading.
The current institutional shareholding score of Abeona Therapeutics Inc is 7.00. The latest institutional shareholding proportion is 70.85%, representing a quarter-over-quarter decrease of 10.33%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
The current risk assessment score of Abeona Therapeutics Inc is 5.60. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.